Higher Scientific Officer - Drug Discovery Biology, Centre for Protein Degradation

We are seeking to recruit a Higher Scientific Officer within the Induced Proximity Therapeutics (IPT) Team in the ICR Centre for Protein Degradation to support our molecular glue and PROTAC drug discovery projects and expand induced proximity technology. The IPT team focuses on three main areas of research :

• Cancer target validation
• Screening, profiling and molecular mechanism of action of molecular glue and PROTAC degraders
• Novel E3 ligase biology and ligand discovery

The successful candidate will work in a multidisciplinary team and play a key role in target validation, developing in vitro and cell-based assays, and pharmacological characterisation of novel molecular glue degraders and PROTACs, but may also contribute to other activities. About you The successful candidate :

Experience in targeted protein degradation will be a significant advantage. Department / Directorate Information This position will be based in the ICR's Centre for Protein Degradation, a part of the Centre for Cancer Drug Discovery (CCDD) specialising in developing novel drug modalities that re-wire tumour cells' signalling by targeted degradation of key oncogenic drivers. Our experienced biologists work closely with medicinal chemists, biophysicists, computational scientists, oncology specialists and physicians on discovering new medicines - molecular glue degraders and PROTACs - using innovative screening platforms and characterising their mechanisms of action, as well as expanding the repertoire of novel degradable drug targets and E3 ligases (enzymes that mediate protein degradation). Our research provides a nucleus for the academics and pharmaceutical industry to explore therapeutic potential of targeted protein degradation from laboratory hypothesis-testing to early clinical trials, for the benefit of cancer patients. What we offer

To learn more about this role, please download the attached job pack. For informal inquiries, please contact Dr Agnieszka Konopacka, Group Leader, Induced Proximity Therapeutics, Centre for Protein Degradation via email : [email protected].